Premium
High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Author(s) -
Murren John R.,
Derosa William,
Durivage Henry J.,
Davis Carol,
Makuch Robert,
Portlock Carol S.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q
Subject(s) - medicine , regimen , dacarbazine , cisplatin , melanoma , chemotherapy , toxicity , gastroenterology , phases of clinical research , metastatic melanoma , surgery , urology , oncology , cancer research
The combination of cisplatin plus dacarbazine (DTIC) is active in metastatic melanoma with response rates reported between 10% and 55%. To optimize this regimen, a Phase II study was conducted employing a dose intensity of cisplatin higher than previously reported. Twenty‐two patients were treated. Eight patients received cisplatin 100 mg/m 2 on days 1 and 8 combined with DTIC 300 mg/m 2 on days 1, 2, 8, and 9 (regimen A). Because of excessive toxicity, the protocol was modified so that cisplatin was given at 50 mg/m 2 per day and DTIC 350 mg/m 2 per day on days 1 through 3 (regimen B). The overall response rate was 32% and consisted of four partial and three complete responses (CR). The median duration of response was 6 months. Two of the CR remain in sustained, unmaintained remission in excess of 1.5 years. All seven patients that responded were treated on regimen B. High‐dose cisplatin plus DTIC on a 3‐day schedule represents an effective, well‐tolerated therapy for metastatic melanoma.